Inactive Instrument

All News Beigene Ltd Hong Kong S.E.

Equities

End-of-day quote Hong Kong S.E. Other stock markets
- ^HKD	-

03:20pm	BeiGene Says Tislelizumab Gets European Commission's Approval to Treat Non-Small Cell Lung Cancer	MT
12:00pm	BeiGene, Ltd. Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer	CI

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BeiGene Says Tislelizumab Gets European Commission's Approval to Treat Non-Small Cell Lung Cancer	09:20am	MT
BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer	06:04am	BU
BeiGene, Ltd. Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer	06:00am	CI
BeiGene to Award Shares Worth $15 Million to 11 Directors	Apr. 17	MT
Western Drugmakers Seeking Alternative Suppliers as US Looks to Restrict Chinese Biotech	Apr. 11	MT
Western Drugmakers Seeking Alternative Suppliers as US Looks to Restrict Chinese Biotech	Apr. 11	MT
BeiGene Opens New Factory in Guangzhou for Antibody-Drug Conjugates	Apr. 10	MT
Beigene Shrinks Loss by 56% in 2023	Mar. 29	MT
Bernstein Adjusts BeiGene's Price Target to $161 From $196, Maintains Market Perform Rating	Mar. 27	MT
Tech Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Slightly Lower in Friday Trading	Mar. 22	MT
BeiGene, Ltd. Announces Executive Changes	Mar. 20	CI
BeiGene Receives FDA Approval for TEVIMBRA for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma after Prior Chemotherapy	Mar. 15	AQ
Beigene's Esophageal Cancer Drug Gets US FDA Nod	Mar. 15	MT
Beigene Insider Sold Shares Worth $8,368,017, According to a Recent SEC Filing	Mar. 14	MT
BeiGene Says FDA Approves Tevimbra to Treat Some Esophageal Cancer Patients	Mar. 14	DJ
BeiGene Gets FDA Approval for Esophageal Cancer Treatment	Mar. 14	MT
BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy	Mar. 14	BU
BeiGene, Ltd. Receives FDA Approval for TEVIMBRA for Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy	Mar. 14	CI
US FDA approves BeiGene's esophageal cancer therapy	Mar. 14	RE
First Doses of BRUKINSA provided to Patients with Chronic Lymphocytic Leukemia in Low and Middle-Income Countries under Collaboration of the Max Foundation, BeiGene, and the BeiGene Foundation	Mar. 14	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Beigene Ltd Hong Kong S.E.

Equities

All News

Filters